rifamycin


Also found in: Dictionary, Wikipedia.
Related to rifamycin: Rifaximin

rifamycin

 [rif″ah-mi´sin]
any of a family of antibiotics biosynthesized by a strain of Streptomyces mediterranei, effective against a broad spectrum of bacteria. The five components are designated A, B, C, D, and E; rifamycins O, S, and SV are derivatives of the B component, and AG and X are derivatives of the O component. Used for the initial treatment and retreatment of pulmonary tuberculosis and for prevention of meningoccal infections in close contacts of patients with Neisseria meningitidis infections.

rifamycin

/rif·a·my·cin/ (rif″ah-mi´sin) any of a family of antibiotics biosynthesized by a strain of Streptomyces mediterranei, effective against a broad spectrum of bacteria, including gram-positive cocci, some gram-negative bacilli, and Mycobacterium tuberculosis and certain other mycobacteria; used for the treatment of tuberculosis and the prophylaxis of meningococcal infections.

rifamycin

(rĭf′ə-mī′sĭn)
n.
Any of a group of antibiotics originally isolated from a strain of the soil microorganism Streptomyces mediterranei, used in the United States to treat tuberculosis and prevent meningococcal infections, and used in other countries to treat leprosy and other bacterial diseases.

rifamycin

[rif′ah-mi′sin]
any of a family of antibiotics biosynthesized from a strain of Streptomyces mediterranei, effective against a broad spectrum of bacteria. The five components are designated A, B, C, D, and E; rifamycins O, S, and SV are derivatives of the B component, and AG and X are derivatives of the O component. It is used for the initial treatment and retreatment of pulmonary tuberculosis and for prevention of meningococcal infections in close contacts of patients with Neisseria meningitidis infections.

rifamycin

a family of antibiotics produced in cultures of Streptomyces mediterranei. Effective against gram-positive cocci and gram-negative bacilli and mycobacteria including Mycobacterium tuberculosis.
References in periodicals archive ?
Rifamycin is a poorly absorbed, broad-spectrum antibiotic in the same chemical family as rifaximin.
Material Active principle Presentation Rifocort[R] Sodium rifamycin SV21-prednisolone Ointment Acetate Nebacetin[R] Neomycin sulfate Ointment Bacitracin 2%-Chlorhexidine 2%-Chlorhexidine digluconate Gel digluconate Maxitrol[R] Neomycin sulfate Ointment Polymyxin b sulfate Dexamethasone Material Properties Rifocort[R] Antimicrobial Antiinflammatory Nebacetin[R] Antimicrobial 2%-Chlorhexidine Antimicrobial digluconate Maxitrol[R] Antimicrobial Antiinflammatory Table 2.
Encouragingly, despite worries of rifamycin resistance, secondary to rifampicin monotherapy in MDT where TB is undetected, (7,16) all patients at our centres were successfully treated for TB with conventional category-I anti-TB chemotherapy.
Rifamycin SV MMX: In September 2012, Santarus announced that patients treated with rifamycin SV MMX demonstrated statistically significant improvement in reducing time to last unformed stool in patients with travelers' diarrhea, the primary endpoint of a Phase III clinical study to evaluate the safety and efficacy of rifamycin SV MMX versus placebo.
Two molecules were tried in this study; Clonazepam (5 [micro]g/mL) and Rifamycin (11.
Rifampicin is a semisynthetic derivative of rifamycin B and inhibits the growth of a variety of bacteria.
The team -- from Leeds' Astbury Centre for Structural Molecular Biology and Faculty of Biological Sciences -- found that an antibiotic known as Rifamycin SV was able to prevent the protein ?
Approved in 2004 for treating travelers' diarrhea caused by noninvasive strains of Escherichia coli in people aged 12 and older, rifaximin is a poorly absorbed oral antibiotic derived from rifamycin, and has a broad spectrum of activity against gram-positive and gram-negative, aerobic and anaerobic enteric bacteria.
Rifaximin, a semisynthetic rifamycin which is nonabsorbable in the gastrointestinal tract, has been available in Europe and other countries for several years and has recently been approved in the US for treatment of traveler's diarrhea.
Drugs like streptomycin and rifamycin, which have worked wonderfully for TB and leprosy, don't work well with M.
HIV-infected persons have a higher risk for acquisition of isolated rifampin resistance (25,26), and once- or twice-weekly rifamycin-based regimens increase the risk for acquired rifamycin resistance in TB patients with advanced HIV disease (27-29).